These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27418108)

  • 21. Sovaldi dilemma likely to get worse.
    Carroll J
    Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
    [No Abstract]   [Full Text] [Related]  

  • 22. [Sofosbuvir/ledipasvir is also effective in routine general practice].
    Warpakowski A
    MMW Fortschr Med; 2016 Apr; 158 Spec No 1():65. PubMed ID: 27090681
    [No Abstract]   [Full Text] [Related]  

  • 23. Healing of autoimmune hepatitis associated with hepatitis C virus infection treated with direct-acting antivirals.
    López Couceiro L; Gómez Domínguez E; Muñoz Gómez R; Castellano Tortajada G; Ibarrola de Andrés C; Fernández Vázquez I
    Rev Esp Enferm Dig; 2019 Feb; 111(2):159-161. PubMed ID: 30449122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
    Mullins C; Gibson W; Klibanov OM
    Nurse Pract; 2015 Nov; 40(11):22-6. PubMed ID: 26474199
    [No Abstract]   [Full Text] [Related]  

  • 25. Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.
    Sise ME
    Hepatology; 2017 Oct; 66(4):1335-1337. PubMed ID: 28650558
    [No Abstract]   [Full Text] [Related]  

  • 26. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Indications for Harvoni.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):6. PubMed ID: 27099890
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients.
    Sawinski D; Lee DH; Doyle AM; Blumberg EA
    Transplantation; 2017 May; 101(5):974-979. PubMed ID: 27467534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient.
    Taibi C; Tempestilli M; D'Avolio A; Garbuglia AR; De Nicolò A; Montalbano M; D'Offizi G
    J Clin Pharm Ther; 2017 Oct; 42(5):621-623. PubMed ID: 28474408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
    Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
    Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
    J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
    Elfeki MA; Abou Mrad R; Modaresi Esfeh J; Zein NN; Eghtesad B; Zervos X; Hanouneh IA; O'Shea R; Carey WD; Alkhouri N
    Transplantation; 2017 May; 101(5):996-1000. PubMed ID: 27631598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach.
    Johnson SW; Ammirati SR; Hartis CE; Weber SF; Morgan MR; Darnell TA; Silwal A; Schmidlin HN; Priest DH
    Int J Antimicrob Agents; 2017 Jun; 49(6):778-781. PubMed ID: 28389353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Rule Requires Some Physicians to Report on Postoperative Visits.
    Pullen LC
    Am J Transplant; 2017 Apr; 17(4):847-848. PubMed ID: 28371537
    [No Abstract]   [Full Text] [Related]  

  • 36. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
    Kwok RM; Ahn J; Schiano TD; Te HS; Potosky DR; Tierney A; Satoskar R; Robertazzi S; Rodigas C; Lee Sang M; Wiegel J; Patel N; Gripshover J; Hassan MA; Branch A; Smith CI
    Liver Transpl; 2016 Nov; 22(11):1536-1543. PubMed ID: 27543748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful evolution of morphea after hepatitis C virus eradication with direct-acting antiviral agent treatment.
    Guerra Romero AR; Pérez Figueras M; Alonso López S
    Rev Esp Enferm Dig; 2019 Dec; 111(12):973. PubMed ID: 31696725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of HCV Infection in Adults with Congenital Heart Disease and Treatment with Direct Antiviral Agents.
    Gade AR; Patel M; West DR; Abrams GA
    South Med J; 2018 Mar; 111(3):137-141. PubMed ID: 29505646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
    Mattingly Ii TJ; Heil EL; Hoke KS
    J Health Care Poor Underserved; 2017; 28(2):621-625. PubMed ID: 28529212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.